mtDNA Structure

• Circular, double-stranded DNA — 16,569 base pairs; located in the mitochondrial matrix
• 37 genes: 13 encode respiratory chain protein subunits, 22 encode tRNAs, 2 encode rRNAs
• No introns, no histones, limited DNA repair mechanisms → 10–17x higher mutation rate than nuclear DNA
• Each cell contains hundreds to tens of thousands of mtDNA copies, with 2–10 mtDNA molecules per mitochondrion (oocytes harbor >100,000 copies)

Inheritance & Heteroplasmy

• Maternal inheritance: mtDNA is transmitted exclusively from the ovum; paternal mitochondria are tagged with ubiquitin and destroyed after fertilization
• An affected mother passes mutant mtDNA to all children, but only daughters transmit further; heteroplasmy levels (and therefore clinical severity) vary widely between siblings due to the genetic bottleneck
• Heteroplasmy: coexistence of normal (wild-type) and mutant mtDNA within the same cell
  • Threshold effect: symptoms manifest when the proportion of mutant mtDNA exceeds a critical threshold (typically 60–90%, varies by tissue and mutation)
  • Tissues with high metabolic demand (brain, muscle, heart, retina) have lower thresholds → affected first
• Mitotic segregation: during cell division, mitochondria are randomly distributed to daughter cells → heteroplasmy levels can shift between generations and tissues
• Genetic bottleneck: during oogenesis, a small number of mtDNA molecules are selected → explains variable severity among siblings from the same mother

Nuclear-Encoded Mitochondrial Genes

• >1,000 nuclear genes encode mitochondrial proteins (imported via translocase complexes TOM/TIM)
• These follow Mendelian inheritance (autosomal recessive or autosomal dominant) — not maternal
• Examples: POLG, SURF1, SUCLA2, COQ8A, TWNK, RRM2B
• Genetic anticipation does NOT apply to mitochondrial disorders — that concept belongs to trinucleotide repeat expansions (e.g., Huntington disease, myotonic dystrophy)

Electron Transport Chain & Oxidative Phosphorylation

• Coenzyme Q10 (ubiquinone): mobile lipid-soluble electron carrier that shuttles electrons from Complex I and Complex II to Complex III; supplementation is the cornerstone of treatment for primary CoQ10 deficiency
• Cytochrome c: mobile electron carrier between Complex III and Complex IV

Laboratory Studies

• Serum lactate: elevated at rest; further increased by exercise; elevated lactate:pyruvate ratio (>20:1) suggests impaired oxidative phosphorylation
• CSF lactate: more specific than serum lactate for CNS mitochondrial dysfunction
• Other metabolic derangements: elevated alanine, elevated CK, low serum carnitine, organic aciduria

Neuroimaging

• MR spectroscopy (MRS): lactate peak appears as a doublet at 1.33 ppm; characteristically inverted (below baseline) at TE 135 ms and upright at TE 35 ms — this inversion pattern distinguishes lactate from lipid
• MRI patterns by syndrome:
  • MELAS: cortical/subcortical lesions NOT following vascular territories, often parieto-occipital, migratory
  • Leigh syndrome: symmetric T2 hyperintensity in basal ganglia and brainstem
  • KSS: white matter T2 signal abnormalities, cerebellar atrophy

Muscle Biopsy

• Ragged red fibers (RRF): subsarcolemmal accumulation of abnormal mitochondria; visualized on modified Gomori trichrome stain as irregular red deposits at fiber periphery
• COX (cytochrome c oxidase) stain: mosaic pattern of COX-negative (pale) and COX-positive (brown) fibers; COX-negative fibers indicate cells where mutant mtDNA has exceeded the threshold
• "Ragged blue" fibers (SDH stain): the SDH-equivalent of ragged-red fibers — intense subsarcolemmal blue SDH staining in fibers with proliferating mitochondria. SDH activity is preserved (and often hyperintense) because Complex II is entirely nuclear-encoded
• COX-negative / SDH-positive fibers on dual COX/SDH staining are conceptually distinct from ragged-blue fibers and are the most specific histochemical marker of mtDNA mutation (loss of mtDNA-encoded COX subunits with preserved nuclear-encoded SDH); the two findings are related but should not be conflated
• Electron microscopy: paracrystalline inclusions within mitochondria, abnormal cristae

Genetic Testing

• mtDNA sequencing: from blood or affected tissue (muscle preferred — heteroplasmy may be undetectable in blood)
• Nuclear gene panels: next-generation sequencing panels for nuclear-encoded mitochondrial genes
• Whole exome/genome sequencing: increasingly used for undiagnosed cases
• Southern blot or long-range PCR for mtDNA deletions (KSS, PEO)

Medications to Avoid

• Valproate: depletes carnitine, inhibits mitochondrial beta-oxidation, and — in patients with POLG mutations — precipitates hepatic mtDNA depletion, producing fulminant hepatic failure (Alpers syndrome); also worsens lactic acidosis. Contraindicated specifically in known/suspected POLG-related disease; use caution and individualize choice in other mitochondrial disorders rather than treating “all mitochondrial disease” as an absolute contraindication
• Aminoglycosides: m.1555A>G mutation in MT-RNR1 (12S rRNA) predisposes to aminoglycoside-induced sensorineural hearing loss
• Statins: may worsen mitochondrial myopathy by impairing CoQ10 biosynthesis — avoid or use with caution in mitochondrial cytopathies
• Metformin: theoretical risk of lactic acidosis in patients with mitochondrial dysfunction (use with caution)

Acquired / Medication-Related Mitochondrial Dysfunction

• Reye syndrome: aspirin exposure in febrile children (especially during viral illness) → microvesicular hepatic steatosis, encephalopathy, and hyperammonemia from acquired mitochondrial dysfunction
• Nucleoside reverse transcriptase inhibitors (e.g., older agents such as stavudine, didanosine) inhibit POLG → mtDNA depletion, neuropathy, myopathy, hepatic steatosis, lactic acidosis
• Linezolid: prolonged courses inhibit mitochondrial protein synthesis → optic neuropathy, peripheral neuropathy, lactic acidosis

Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes

• Most common mutation: m.3243A>G in MTTL1 gene (mitochondrial tRNA-Leu) — accounts for ~80% of MELAS cases
• Onset: childhood to young adulthood (typically 5–15 years); preceded by normal early development
• Stroke-like episodes:
  • Acute neurological deficits resembling stroke (hemiparesis, hemianopia, aphasia)
  • Critical distinction: lesions do NOT conform to vascular territories — they are cortical, often parieto-occipital, and may migrate or shift on serial imaging
  • Thought to result from mitochondrial angiopathy and neuronal energy failure, not thromboembolism
• Seizures: common during stroke-like episodes; focal or generalized; status epilepticus may occur
• Other features: migraine-like headaches, recurrent emesis, encephalopathy, dementia

Systemic Manifestations

• Short stature
• Diabetes mellitus (maternally inherited diabetes and deafness — MIDD — same m.3243A>G mutation)
• Sensorineural hearing loss
• Cardiomyopathy (hypertrophic or dilated)
• Myopathy with exercise intolerance and elevated CK
• Lactic acidosis — persistent elevation, worsened by illness or metabolic stress

Imaging

• MRI: cortical/subcortical T2/FLAIR hyperintensity, NOT following vascular territories; predilection for parietal and occipital lobes; lesions may resolve in one area and appear in another ("migratory")
• MRS: elevated lactate peak
• DWI: may show restricted diffusion during acute stroke-like episodes (cytotoxic edema from energy failure)

Treatment

• IV L-arginine during acute stroke-like episodes — improves nitric oxide availability and endothelial function, with evidence for shorter episode duration and severity
• Oral L-arginine ± citrulline for prophylaxis between episodes
• Supportive: aggressive seizure control, treat lactic acidosis, avoid metabolic stressors

MIDD (Maternally Inherited Diabetes and Deafness)

• Allelic phenotype of the same m.3243A>G mutation — presents with diabetes mellitus and sensorineural hearing loss without the classic stroke-like episodes or encephalopathy of MELAS
• Lower heteroplasmy levels (and/or tissue distribution) likely explain the milder phenotype

Myoclonus Epilepsy with Ragged Red Fibers

• Most common mutation: m.8344A>G in MTTK gene (mitochondrial tRNA-Lys) — ~80% of cases
• Core features:
  • Myoclonus — action myoclonus, stimulus-sensitive; progressive
  • Generalized epilepsy — myoclonic and generalized tonic-clonic seizures
  • Cerebellar ataxia
  • Myopathy with ragged red fibers on biopsy
• Distinctive feature: multiple symmetric lipomatosis (Madelung disease pattern — lipomas of neck, shoulders, trunk)
• Other features: sensorineural hearing loss, optic atrophy, short stature, peripheral neuropathy, dementia
• Biopsy: classic ragged red fibers; COX-negative fibers

Clinical Features

• Genetic basis: large-scale single mtDNA deletion (typically 1–10 kb); the most common is a 4,977-bp "common deletion"
• Onset before age 20 (obligatory diagnostic criterion)
• Diagnostic triad:
  • Progressive external ophthalmoplegia (PEO) — symmetric ptosis and limitation of eye movements in all directions; diplopia is uncommon because both eyes are affected symmetrically
  • Pigmentary retinopathy — characteristically a salt-and-pepper pigmentary retinopathy (usually distinct from the bone-spicule pattern of typical retinitis pigmentosa, though overlap can occur)
  • Cardiac conduction defects — progressive heart block (first degree → complete heart block); can be fatal → all KSS patients require regular cardiac monitoring and may need pacemaker implantation
• Plus at least one of: CSF protein >100 mg/dL, cerebellar ataxia, short stature
• Other features: sensorineural hearing loss, endocrinopathies (diabetes, hypoparathyroidism), renal tubular acidosis
• Sporadic: large mtDNA deletions are almost never inherited (they arise de novo) — unlike point mutations

Pearson Syndrome

• Infantile end of the single large-scale mtDNA deletion spectrum — same deletion class as KSS
• Sideroblastic anemia (transfusion-dependent) plus exocrine pancreatic insufficiency
• Many affected infants die in early childhood; survivors evolve into the KSS phenotype as hematologic disease wanes and PEO/retinopathy/cardiac conduction disease emerge

Leber Hereditary Optic Neuropathy

• Three primary point mutations (account for ~95% of cases):
  • m.11778G>A (ND4, Complex I) — most common worldwide (~70%); worst visual prognosis
  • m.3460G>A (ND1, Complex I) — intermediate prognosis
  • m.14484T>C (ND6, Complex I) — best visual prognosis (highest rate of spontaneous recovery)
• All three mutations affect Complex I subunits
• Demographics: predominantly affects young males (peak onset 15–35 years); approximately ~50% of male carriers and ~10–15% of female carriers develop visual loss (incomplete penetrance, strong male bias)

Clinical Presentation

• Painless, subacute, sequential bilateral vision loss
  • Central or cecocentral scotoma → severe visual loss (often 20/200 or worse)
  • Second eye affected within weeks to months of the first (rarely simultaneous)
• Fundoscopic findings (acute phase):
  • Pseudoedema of the optic disc (peripapillary nerve fiber layer swelling without true leakage on fluorescein angiography)
  • Peripapillary telangiectatic microangiopathy (tortuous small vessels around the disc)
  • No true disc edema or leakage on fluorescein angiography — distinguishes from papilledema and optic neuritis
• Late phase: optic atrophy (pallor of the temporal disc, then diffuse)
• No ragged red fibers on muscle biopsy — LHON primarily affects retinal ganglion cells

Treatment

• Idebenone (synthetic short-chain CoQ10 analog): EMA-approved (not FDA-approved) for LHON; modest benefit on visual recovery, particularly with early treatment and m.11778G>A or m.3460G>A mutations
• Avoid: smoking and excessive alcohol intake (worsen penetrance)
• Lenadogene nolparvovec — investigational AAV2-ND4 gene therapy delivering wild-type ND4 for m.11778G>A LHON; the EMA marketing authorization application was withdrawn/refused, so it is NOT EU-approved and is not FDA-approved

Neuropathy, Ataxia, and Retinitis Pigmentosa

• Mutation: m.8993T>G or m.8993T>C in MT-ATP6 gene (Complex V — ATP synthase)
• Core triad:
  • Sensory neuropathy (axonal)
  • Cerebellar ataxia
  • Retinitis pigmentosa
• Other features: seizures, developmental delay, proximal weakness, learning disability
• Heteroplasmy-phenotype correlation:
  • Mutant load <70%: often asymptomatic
  • Mutant load 70–90%: NARP phenotype
  • Mutant load >90%: Leigh syndrome phenotype (severe infantile encephalopathy)
• The NARP/Leigh spectrum is one of the best clinical examples of the heteroplasmy threshold effect

Subacute Necrotizing Encephalomyelopathy

• Most common mitochondrial disease of infancy
• Genetically heterogeneous: can be caused by mtDNA mutations (MT-ATP6, ND genes) or nuclear gene mutations (SURF1, NDUFS genes, PDHA1, SUCLA2, and many others)
• Clinical features:
  • Onset typically in infancy or early childhood (3 months to 2 years)
  • Developmental regression, failure to thrive
  • Hypotonia, feeding difficulties, vomiting
  • Respiratory abnormalities (central hypoventilation, apnea, sighing respiration)
  • Movement disorders (dystonia, choreoathetosis)
  • Optic atrophy, ophthalmoparesis
• Characteristic MRI: symmetric, bilateral T2 hyperintensity in the basal ganglia (putamen, caudate) and brainstem (periaqueductal gray, substantia nigra, inferior olivary nuclei) — representing necrotizing lesions
• Elevated lactate in serum and CSF
• Prognosis is poor; most patients die in childhood from respiratory failure

Key Genetic Causes of Leigh Syndrome

Chronic Progressive External Ophthalmoplegia (CPEO)

• Clinical hallmark: slowly progressive bilateral ptosis and limitation of eye movements in all directions of gaze; diplopia is rare because involvement is symmetric
• Orbicularis oculi weakness (cannot bury eyelashes) is often present
• Mild proximal myopathy, exercise intolerance
• Ragged red fibers and COX-negative fibers on muscle biopsy

Genetic Causes

• Sporadic: single large-scale mtDNA deletions (same type as KSS but presenting later in life, without cardiac or retinal features)
• Autosomal dominant PEO: mutations in POLG, TWNK (Twinkle helicase), RRM2B, SLC25A4 → cause secondary multiple mtDNA deletions
• Autosomal recessive PEO: POLG mutations (most common), TWNK, RRM2B

POLG-Related Disorders

• POLG encodes the catalytic subunit of mitochondrial DNA polymerase gamma — the only DNA polymerase in mitochondria
• Wide phenotypic spectrum:
  • Alpers syndrome (Alpers-Huttenlocher): childhood-onset progressive encephalopathy with intractable seizures and liver failure; valproate is absolutely contraindicated (precipitates fatal hepatotoxicity)
  • SANDO: sensory ataxic neuropathy, dysarthria, and ophthalmoparesis
  • MIRAS: mitochondrial recessive ataxia syndrome
  • MEMSA: myoclonic epilepsy, myopathy, sensory ataxia
  • CPEO (AD or AR)
  • Epilepsy with valproate sensitivity
• Collectively, SANDO / MIRAS / MEMSA are grouped under the POLG ataxia-neuropathy spectrum (ANS)
• Inheritance is autosomal recessive for severe phenotypes (Alpers, SANDO) and can be AD or AR for PEO

Key Nuclear-Encoded Mitochondrial Diseases

MNGIE (Mitochondrial Neurogastrointestinal Encephalomyopathy)

• Gene: TYMP (autosomal recessive) → thymidine phosphorylase deficiency → toxic accumulation of plasma thymidine and deoxyuridine → imbalanced mitochondrial nucleotide pool → secondary mtDNA depletion, deletions, and point mutations
• Clinical tetrad:
  • GI dysmotility / chronic intestinal pseudo-obstruction with severe cachexia (often the presenting feature)
  • PEO and ptosis
  • Sensorimotor peripheral neuropathy (demyelinating features common)
  • Diffuse leukoencephalopathy on MRI (often asymptomatic radiographic finding)
• Treatment: allogeneic hematopoietic stem cell transplantation (HSCT) restores thymidine phosphorylase activity; erythrocyte-encapsulated thymidine phosphorylase is an emerging enzyme-replacement strategy

Mitochondrial Replacement Therapy (MRT)

• UK-approved in 2015 for prevention of transmission of severe mtDNA disease — not for treatment of established disease
• Techniques: pronuclear transfer and maternal spindle transfer — the affected mother's nuclear genome is moved into a donor oocyte that has been enucleated, leaving the donor's healthy mtDNA in place
• The resulting child carries nuclear DNA from two parents and mtDNA from a third (mitochondrial) donor